bioAffinity Technologies, Inc.
Index- P/E- EPS (ttm)- Insider Own12.70% Shs Outstand8.37M Perf Week-10.73%
Market Cap20.85M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.22M Perf Month45.62%
Income- PEG- EPS next Q- Inst Own0.80% Short Float / Ratio0.73% / 0.03 Perf Quarter-11.41%
Sales0.00M P/S8487.38 EPS this Y13.00% Inst Trans- Short Interest0.05M Perf Half Y-
Book/sh1.51 P/B1.54 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.51 P/C1.54 EPS next 5Y- ROE- 52W Range1.31 - 15.55 Perf YTD45.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.02% Beta-
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low77.86% ATR0.36
Employees11 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)52.12 Volatility8.76% 18.92%
OptionableNo Debt/Eq0.06 EPS Q/Q-208.30% Profit Margin- Rel Volume0.05 Prev Close2.40
ShortableYes LT Debt/Eq0.00 EarningsNov 14 BMO Payout- Avg Volume1.31M Price2.33
Recom- SMA207.47% SMA508.16% SMA200-15.41% Volume70,059 Change-2.92%
Jan-24-23 08:00AM
Jan-04-23 08:00AM
Dec-19-22 11:33AM
Dec-15-22 08:30AM
Dec-01-22 08:00AM
07:30AM Loading…
Nov-14-22 07:30AM
Nov-10-22 08:15AM
Nov-08-22 08:00AM
Oct-25-22 09:15AM
Oct-12-22 08:15AM
Sep-28-22 08:15AM
Sep-14-22 08:15AM
Sep-06-22 01:54PM
Sep-01-22 12:32PM
08:15AM Loading…
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.